R 8oh dpat hydrobromide

5-HT (Sigma-Aldrich, St Louis, MO) was prepared fresh daily as a 2mM aqueous stock and diluted into extracellular solution at final working concentrations of 25 nM - 10μM. Escitalopram oxalate (20mM), (R)-(+)-8OH-DPAT hydrobromide (50mM) (both Sigma-Aldrich, St Louis, MO), WAY100635 maleate (25mM) (Abcam, Cambridge, MA), CP93129 dihydrochloride (50mM) (R&D systems, Minneapolis, MN) and TTX (1mM) (R&D systems, Minneapolis, MN) were all prepared as aqueous stock solutions and frozen in aliquots. All stock solutions were diluted (> 1000×) to a final working concentration in extracellular solution or KCl stimulation solution on the day of use. Gallein (R&D systems, Minneapolis, MN) was prepared as a 30mM stock solution in DMSO on the day of use and diluted to 10μM working concentration (0.03% DMSO). Fura-2AM was prepared as a 1mM stock solution in DMSO and aliquots stored at −20 C for no more than 1-2 weeks. Stocks were diluted into HEPES-buffered Hank’s balanced salt solution on the day of use.

(R)-(+)-8-OH-DPAT hydrobromide ((R)-(+)-2-Dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide) and WAY100635 maleate salt (N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide maleate salt) were purchased from Sigma-Aldrich(St Louis, MO). CCG-203769 was synthesized as previously described (Blazer et al., 2015 (link)). [³H] 8-OH-DPAT was from Perkin Elmer (Waltham, MA).